(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia. Read More
PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Notes that deupirfenidone, also known as LYT-100, slows lung function decline in people with idiopathic pulmonary fibrosis as measured by forced vital capacity in a phase 2b trial. Toby Maher, professor of medicine & director of interstitial lung disease at Keck School of Medicine at the University of Southern California in Los Angeles, and lead investigator in the Elevate IPF trial, says: "Deupirfenidone has the potential to offer patients a highly effective and tolerable treatment option. These are extremely exciting results from a phase 2b trial, and I am very enthusiastic about the continued development of deupirfenidone." Read More
(Alliance News) - London's FTSE 100 is called to open slightly lower on Thursday, despite US stocks spiking to record highs overnight. Read More
(Alliance News) - Frasers Group PLC has been relegated from the FTSE 100 index in its latest quarterly shuffle alongside two constituent peers, housebuilder Vistry Group PLC and variety goods retailer B&M European Value Retail SA. Read More
(Alliance News) - PureTech Health PLC on Wednesday said a new patient survey for people with idiopathic pulmonary fibrosis has provided new insights into disease burden and patient experience. Read More
(Alliance News) - PureTech Health PLC on Friday said KarXT has received US Food & Drug Administration approval for treating schizophrenia. Read More
(Alliance News) - Stock prices in London opened somewhat higher on Friday, as investors wait for the US personal consumption expenditure data, plus various European consumer price and confidence readings. Read More
(Alliance News) - European stocks were called to open higher on Friday, ahead of US personal consumption expenditure and other important US data. Read More
PureTech Health PLC - Boston, Massachusetts-based biotechnology company - Founded entity Vor Bio, a clinical stage cell and genome engineering company, has received new clinical data from ongoing Phase 1/2 VBP101 study. The study looks at patients with relapsed or refractory acute myeloid leukaemia receiving trem-cel followed by the Mylotarg drug. Recent data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit. Read More
(Alliance News) - Stock prices in London opened lower on Friday, as the market prepares for jobs data from the US following an ADP report on Thursday. Read More
(Alliance News) - Stocks were called lower on Friday, joining peers in the US and Asia, ahead of a GDP print from the eurozone later in the day, and following a data-heavy week globally. Read More
(Correcting PureTech Health PLC half-year revenue and pretax loss.) Read More
(Alliance News) - PureTech Health PLC on Wednesday reported a widened loss and lower revenue, as it attempted to address shareholder concerns voiced at its June annual general meeting. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
PureTech Health PLC - London-listed Biotech company headquartered in Boston - Says Tuesday that founded entity, Ankili Inc, a game developer focusing on improving mental health, will merge with Virtual Therapeutics Corp, a Boston-based digital therapeutics company. As of May 7, PureTech owned over 12.5 million of Ankili common stock. Read More
(Alliance News) - PureTech Health PLC on Tuesday said that a company it founded and in which it maintains a stake had begun trials of a new treatment for clostridioides difficile infection, in the hopes of moving toward regulatory approval. Read More
PureTech Health PLC - London-based biotherapeutics company - Launches tender offer to repurchase shares for a maximum consideration of USD100 million. The offer, set to run until June 18, will be for up to 33.5 million shares, around 12% of PureTech's share capital, at a fixed price of 250 pence each. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More